Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Helen Mani"'
Autor:
Gundolf Schuettfort, Birgit Linnemann, Eva Herrmann, Thomas Wendt, Edelgard Lindhoff-Last, Helen Mani, Natalie Herth, Alexander Kasper, Yvonne Weil, Waltraud Pfeilschifter
Publikováno v:
Therapeutic Drug Monitoring. 36:624-631
This investigation was carried out with already available point-of-care testing (POCT) systems for coagulation parameters to evaluate the qualitative and semiquantitative determination of the time- and concentration-dependent anticoagulant effects of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8418d3d93efb0102ca59483ee72e38f2
https://doi.org/10.1097/ftd.0000000000000064
https://doi.org/10.1097/ftd.0000000000000064
Publikováno v:
Der Klinikarzt. 42:40-46
Um die orale Antikoagulation zu vereinfachen und zu optimieren, sind neue Wirkstoffe entwickelt worden, die spezifisch einen einzelnen Gerinnungsfaktor hemmen. Der direkte Thrombininhibitor Dabigatran sowie die direkten Faktor-Xa-Hemmer Rivaroxaban u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a12e486959a139e0c255833f06adf9b
https://doi.org/10.1055/s-0033-1347022
https://doi.org/10.1055/s-0033-1347022
Publikováno v:
Journal of Thrombosis and Thrombolysis. 36:187-194
To simplify and optimize oral anticoagulation, new target-specific oral anticoagulants (TSOAs) have been developed. The direct thrombin-inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban are the first such com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c065acf1f8460ad35e7a60ec47b0818
https://doi.org/10.1007/s11239-013-0907-y
https://doi.org/10.1007/s11239-013-0907-y
Publikováno v:
Thrombosis and Haemostasis. 109:127-136
SummaryGlobal coagulation assays display variable effects at different concentrations of rivaroxaban. The aim of this study is to quantify the ex vivo effects of low-dose rivaroxaban on thrombophilia screening assays and coagulation factor activities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::915bc5ac910c250cde0c8ae1457edcde
https://doi.org/10.1160/th12-04-0228
https://doi.org/10.1160/th12-04-0228
Autor:
Christian Hesse, Gabriele Rohde, Natalie Herth, Helen Mani, Gertrud Stratmann, Stephan Schwers, Edelgard Lindhoff-Last, Elisabeth Perzborn
Publikováno v:
Thrombosis and Haemostasis. 108:191-198
SummaryRivaroxaban is a direct factor Xa inhibitor, which can be monitored by anti-factor Xa chromogenic assays. This ex vivo study evaluated different assays for accurate determination of rivaroxaban levels. Eighty plasma samples from patients recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c298877bf49b60839095db8fc5e7bea
https://doi.org/10.1160/th11-12-0832
https://doi.org/10.1160/th11-12-0832
Publikováno v:
Thrombosis and Haemostasis. 106:156-164
SummaryIt was the objective of this study to quantify the effects of rivaroxaban administration on global coagulation parameters associated with routine clinical procedures, we collected plasma samples from patients undergoing major orthopaedic surge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57d4de9b56f71fbd84e2e2be1ec01940
https://doi.org/10.1160/th10-10-0667
https://doi.org/10.1160/th10-10-0667
Publikováno v:
Atherosclerosis. 209:504-509
Residual platelet function despite treatment with clopidogrel may predict an unfavourable cardiovascular outcome. The majority of studies have investigated the effects of clopidogrel administration in conjunction with aspirin in patients undergoing p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadc3bd6c7027d6d4b96ca2ed67dcbbc
https://doi.org/10.1016/j.atherosclerosis.2009.05.039
https://doi.org/10.1016/j.atherosclerosis.2009.05.039
Publikováno v:
Annals of Hematology. 89:597-605
Until now, the PFA-100® system has been considered unsuitable for monitoring clopidogrel efficacy. The authors evaluated platelet function in peripheral arterial occlusive disease (PAOD) patients using a new PFA-100® test cartridge (product name: I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bf03c4280d5743d3ee9b7f9d3267da
https://doi.org/10.1007/s00277-009-0881-9
https://doi.org/10.1007/s00277-009-0881-9
Autor:
Edelgard Lindhoff-Last, Helen Mani
Publikováno v:
Pharmazie in unserer Zeit. 38:342-350
Die Therapie mit ASS oder Clopidogrel variiert stark. Mit Hilfe verschiedener Thrombozytenfunktionstests konnte gezeigt werden, dass Subgruppen von Patienten unter ASS- und/oder Clopidogrel-Therapie den erwarteten plattchenhemmenden Effekt vermissen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c7d6ad3ac14ce375bb7d295b8149340
https://doi.org/10.1002/pauz.200900324
https://doi.org/10.1002/pauz.200900324
Autor:
François Mullier, Bernard Chatelain, Valentine Minet, Helen Mani, Jonathan Douxfils, Jean-Michel Dogné, Bérangère Devalet
Publikováno v:
BioMed Research International, Vol 2015 (2015)
BioMed Research International
BioMed Research International
Non-VKA oral anticoagulants (NOACs) have now widely reached the lucrative market of anticoagulation. While the marketing authorization holders claimed that no routine monitoring is required and that these compounds can be given at fixed doses, severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b65d4b056440627de1fa8bf1eaa73981
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54311
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54311
